These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34690116)

  • 41. Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia.
    Kane JM; Correll CU
    J Clin Psychiatry; 2019 Sep; 80(5):. PubMed ID: 31536686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime?: A Naturalistic, Long-Term Follow-Up Study.
    Glick ID; Davis JM; Zamora D; Ballon J; Nuthi M
    J Clin Psychopharmacol; 2017 Apr; 37(2):125-130. PubMed ID: 28195931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication.
    Moncrieff J; Azam K; Johnson S; Marston L; Morant N; Darton K; Wood N
    BMC Psychiatry; 2016 Jul; 16():205. PubMed ID: 27377549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study.
    Aguglia A; Fusar-Poli L; Amerio A; Placenti V; Concerto C; Martinotti G; Carrà G; Bartoli F; D'Agostino A; Serafini G; Amore M; Aguglia E; Ostuzzi G; Barbui C;
    Front Psychiatry; 2021; 12():784366. PubMed ID: 34975581
    [No Abstract]   [Full Text] [Related]  

  • 45. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
    Kane JM; Sanchez R; Baker RA; Eramo A; Peters-Strickland T; Perry PP; Johnson BR; Tsai LF; Carson WH; McQuade RD; Fleischhacker WW
    Clin Schizophr Relat Psychoses; 2015; 9(2):79-87. PubMed ID: 25711509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.
    Bitter I; Treuer T; Dilbaz N; Oyffe I; Ciorabai EM; Gonzalez SL; Ruschel S; Salburg J; Dyachkova Y
    World J Biol Psychiatry; 2010 Oct; 11(7):894-903. PubMed ID: 20653494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):23S-9S. PubMed ID: 23945064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
    Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
    J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial.
    Kane JM; Schooler NR; Marcy P; Achtyes ED; Correll CU; Robinson DG
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 31050233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Satisfaction with antipsychotics as a medication: the role of therapeutic alliance and patient-perceived participation in decision making in patients with schizophrenia spectrum disorder.
    Torrecilla-Olavarrieta R; Pérez-Revuelta J; García-Spínola E; López Martín Á; Mongil-SanJuan JM; Rodríguez-Gómez C; Villagrán-Moreno JM; González-Saiz F
    Int J Psychiatry Clin Pract; 2021 Sep; 25(3):268-276. PubMed ID: 32787650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antipsychotic medication adherence and satisfaction among Palestinian people with schizophrenia.
    Sweileh WM; Ihbesheh MS; Jarar IS; Sawalha AF; Abu Taha AS; Zyoud SH; Morisky DE
    Curr Clin Pharmacol; 2012 Feb; 7(1):49-55. PubMed ID: 22299769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subjective Medication Satisfaction With Antipsychotic Polypharmacy in a Naturalistic Inpatient and Outpatient Sample.
    Kikkert MJ; de Mooij L; de Koning M; Dekker J
    J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34936243
    [No Abstract]   [Full Text] [Related]  

  • 55. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication.
    Campagna EJ; Muser E; Parks J; Morrato EH
    J Manag Care Spec Pharm; 2014 Jul; 20(7):756-66. PubMed ID: 24967528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
    Aggarwal NK; Sernyak MJ; Rosenheck RA
    J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differences in medication adherence, satisfaction and clinical symptoms in schizophrenic outpatients taking different antipsychotic regimens.
    Sweileh WM; Ihbesheh MS; Jarar IS; Sawalha AF; Abu Taha AS; Zyoud SH; Morisky DE
    Curr Drug Saf; 2011 Nov; 6(5):285-90. PubMed ID: 22424535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial.
    Priebe S; Bremner SA; Lauber C; Henderson C; Burns T
    Health Technol Assess; 2016 Sep; 20(70):1-122. PubMed ID: 27682868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients.
    Iasevoli F; Fagiolini A; Formato MV; Prinzivalli E; Giordano S; Balletta R; De Luca V; de Bartolomeis A
    Psychiatry Res; 2017 Mar; 249():159-166. PubMed ID: 28104562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.